APA

Pettitt A. R., Jackson R., Carruthers S., Dodd J., Dodd S., Oates M., Johnson G. G., Schuh A., Matutes E., Dearden C. E., Catovsky D., Radford J. A., Bloor A., Follows G. A., Devereux S., Kruger A., Blundell J., Agrawal S., Allsup D., Proctor S., Heartin E., Oscier D., Hamblin T. J., Rawstron A. & Hillmen P. (20120712). Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chicago

Pettitt Andrew R, Jackson Richard, Carruthers Stacey, Dodd James, Dodd Susanna, Oates Melanie, Johnson Gillian G, Schuh Anna, Matutes Estella, Dearden Claire E, Catovsky Daniel, Radford John A, Bloor Adrian, Follows George A, Devereux Stephen, Kruger Anton, Blundell Julie, Agrawal Samir, Allsup David, Proctor Stephen, Heartin Earnest, Oscier David, Hamblin Terry J, Rawstron Andrew and Hillmen Peter. 20120712. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Harvard

Pettitt A. R., Jackson R., Carruthers S., Dodd J., Dodd S., Oates M., Johnson G. G., Schuh A., Matutes E., Dearden C. E., Catovsky D., Radford J. A., Bloor A., Follows G. A., Devereux S., Kruger A., Blundell J., Agrawal S., Allsup D., Proctor S., Heartin E., Oscier D., Hamblin T. J., Rawstron A. and Hillmen P. (20120712). Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MLA

Pettitt Andrew R, Jackson Richard, Carruthers Stacey, Dodd James, Dodd Susanna, Oates Melanie, Johnson Gillian G, Schuh Anna, Matutes Estella, Dearden Claire E, Catovsky Daniel, Radford John A, Bloor Adrian, Follows George A, Devereux Stephen, Kruger Anton, Blundell Julie, Agrawal Samir, Allsup David, Proctor Stephen, Heartin Earnest, Oscier David, Hamblin Terry J, Rawstron Andrew and Hillmen Peter. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20120712.